High-throughput screening for antihypertensive prescribing cascades
抗高血压处方级联的高通量筛选
基本信息
- 批准号:10682502
- 负责人:
- 金额:$ 11.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdherenceAdrenergic beta-AntagonistsAdultAdverse drug eventAdverse effectsAdverse eventAgeAmericanAntihypertensive AgentsBiologicalBlood PressureCalcium Channel BlockersCardiovascular systemChronicClassificationClinicalCollectionDataData AnalysesData ScienceData SourcesDatabasesDetectionDiseaseDisparityDiureticsDrug PrescriptionsEconomicsEdemaElderlyEthnic OriginExposure toFailureFutureGenerationsGoalsGuidelinesHypertensionIndividualInsuranceIntervention StudiesInvestigationKnowledgeLabelMedicareMedicineMethodologyNational Heart, Lung, and Blood InstituteOutcomePatientsPharmaceutical PreparationsPhysiciansPolypharmacyPreventionProcessQuality of lifeRaceRecordsRegimenResearchResourcesSignal TransductionSubgroupSymptomsTestingTimeWorkblood pressure controlcandidate identificationcardiovascular risk factorclinical decision supportclinically significantcostfrontierhigh throughput screeninghuman diseaseinnovationnovelprecision drugspreventscreeningsexside effectthiazide
项目摘要
PROJECT SUMMARY
Hypertension (HTN) is prevalent in nearly half of U.S. adults and treated with >3 million antihypertensive
prescription fills per day in the U.S. Although commonly-used antihypertensives are generally well-tolerated,
their ubiquitous use exposes millions of adults to potentially treatment-limiting adverse events (AEs), some of
which are well-known, but many are non-specific or indistinguishable from HTN-related symptoms and not
easily attributed to the offending antihypertensive. Failure to associate these AEs with the causative agent may
prompt additional therapy to treat the AE—known as a “prescribing cascade”—with potentially important
implications regarding polypharmacy, unnecessary costs, exposure to additional side effects, treatment
nonadherence, and reduced quality of life, especially in older adults. Most prescribing cascade studies to date
have been narrowly focused on drugs with a well-known AE that is highly specific to the drug, severely limiting
our understanding of prescribing cascades occurring due to less well-known or non-specific AEs. This
approach has resulted in slow knowledge generation and missed opportunities for comprehensively assessing
and discovering new prescribing cascades. In line with NHLBI Strategic Objective 7 to “leverage emerging
opportunities in data science to open new frontiers in research,” this proposal seeks to develop and utilize a
novel methodologic approach for high-throughput screening of prescribing cascades and discover novel
antihypertensive prescribing cascades using a nationally-representative administrative claims data source.
This goal will be achieved via the following Aims: 1) elucidate candidate antihypertensive-related prescribing
cascades using the SIDe Effect Resource, a collection of prescription labeling which include drug AEs and
drug indications; 2) identify prescribing cascade signals occurring during real world use of antihypertensives
using a Medicare database; and, 3) classify cascade signal detection and prioritize further research via an
expert panel. The proposed work is expected to 1) identify and characterize the magnitude of common
antihypertensive prescribing cascades, including those previously unknown; 2) develop an efficient framework
for wide-scale assessment of prescribing cascade detection; and, 3) establish the basis for a compendium of
known cascades. This proposal also builds logically towards future research applying this framework for
discovery of prescribing cascades with cardiovascular (and other) treatments, assessing downstream
consequences of prescribing cascades, and testing clinical decision support aids to prevent prescribing
cascades.
项目总结
高血压(HTN)在近一半的美国成年人中很普遍,并接受了300万英镑的抗高血压药物治疗
尽管常用的降压药一般耐受性良好,
它们的普遍使用使数百万成年人暴露于可能限制治疗的不良事件(AEs),其中一些
这些都是众所周知的,但其中许多是非特异性的或与HTN相关的症状无法区分
很容易归因于令人不快的抗高血压药。未能将这些不良反应与致病因素联系起来可能
催促额外的治疗方法来治疗AE--也就是所谓的“处方级联”--具有潜在的重要性
关于多药、不必要的费用、暴露于额外副作用、治疗的影响
不坚持,生活质量下降,特别是在老年人中。迄今为止最多的处方级联研究
一直狭隘地专注于具有众所周知的AE的药物,这种药物对药物具有高度特异性,严重限制了
我们对由于不太知名或非特定的血管紧张素转换酶引起的级联反应的理解。这
这种方法导致知识生成缓慢,并错失了全面评估的机会
以及发现新的处方级联。与NHLBI战略目标7保持一致,即“利用新兴市场
数据科学中的机会,以开辟研究的新领域,“这项建议寻求开发和利用
高通量筛选处方级联和发现新药的新方法
使用具有全国代表性的行政索赔数据来源的抗高血压处方级联。
这一目标将通过以下目标来实现:1)阐明与降压相关的候选处方
使用副作用资源的级联,这是一个包括药物不良反应和药物不良反应的处方标签集合
药物适应症;2)识别在实际使用抗高血压药物期间出现的处方级联信号
使用Medicare数据库;以及3)对级联信号检测进行分类,并通过
专家小组。预计拟议的工作将1)确定和表征共同的
抗高血压处方级联,包括那些以前未知的;2)开发有效的框架
用于处方级联检测的大范围评估;以及,3)为
已知的瀑布。这一建议也为应用这一框架的未来研究奠定了逻辑基础
发现用心血管(和其他)治疗方法开出级联,评估下游
开出连锁处方的后果,并测试临床决策辅助工具以防止开处方
瀑布。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven Michael Smith其他文献
MACHINE LEARNING PREDICTION MODEL OF BLOOD PRESSURE VARIABILITY
- DOI:
10.1016/s0735-1097(22)02572-4 - 发表时间:
2022-03-08 - 期刊:
- 影响因子:
- 作者:
Osama Dasa;Chen Bai;Mamoun Mardini;Steven Michael Smith;Eileen M. Handberg;Carl J. Pepine - 通讯作者:
Carl J. Pepine
Steven Michael Smith的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven Michael Smith', 18)}}的其他基金
High-throughput screening for antihypertensive prescribing cascades
抗高血压处方级联的高通量筛选
- 批准号:
10516334 - 财政年份:2022
- 资助金额:
$ 11.44万 - 项目类别:
Advancing Personalized Hypertension Care through Big Data Science
通过大数据科学推进个性化高血压护理
- 批准号:
10439511 - 财政年份:2018
- 资助金额:
$ 11.44万 - 项目类别:
Advancing Personalized Hypertension Care through Big Data Science
通过大数据科学推进个性化高血压护理
- 批准号:
10229379 - 财政年份:2018
- 资助金额:
$ 11.44万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 11.44万 - 项目类别:
Fellowship Programs














{{item.name}}会员




